Eron L J, Goldenberg R I, Park C H, Poretz D M
Antimicrob Agents Chemother. 1983 Feb;23(2):236-41. doi: 10.1128/AAC.23.2.236.
Ceftazidime, a new broad-spectrum cephalosporin, was administered to 30 patients with serious bacterial infections in a randomized dosing trial with daily doses of 1.5 or 3 g. Both regimens were equally efficacious, with satisfactory clinical responses in 28 instances (93%) and microbiological eradication of 79% of initial bacterial isolates. The development of resistance to ceftazidime during therapy was observed in three cases (Enterobacter agglomerans, Enterobacter cloacae, and Pseudomonas aeruginosa) and superinfection by a resistant Enterobacter agglomerans strain occurred in one case. Adverse reactions of clinical significance included one case each of leukopenia, azotemia, diarrhea (Clostridium difficile toxin positive), and rash.
头孢他啶是一种新型广谱头孢菌素，在一项随机给药试验中，对30例严重细菌感染患者每日给予1.5克或3克剂量。两种给药方案疗效相当，28例（93%）临床反应良好，79%的初始分离细菌实现微生物学清除。治疗期间观察到3例（聚团肠杆菌、阴沟肠杆菌和铜绿假单胞菌）出现对头孢他啶的耐药性，1例发生耐聚团肠杆菌菌株的二重感染。具有临床意义的不良反应包括白细胞减少、氮质血症、腹泻（艰难梭菌毒素阳性）和皮疹各1例。
